Cardiol Therapeutics (CRDL)
(Real Time Quote from BATS)
$2.26 USD
+0.04 (1.80%)
Updated May 22, 2024 11:36 AM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRDL 2.26 +0.04(1.80%)
Will CRDL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
Other News for CRDL
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
Analysts Conflicted on These Healthcare Names: Cardiol Therapeutics (CRDL) and MicroPort Scientific (OtherMCRPF)
Cardiol Therapeutics Advances Heart Disease Trials
Cardiol Therapeutics Advances Heart Disease Trials